A Study of LY2409021 in Participants With Different Levels of Kidney Function

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to measure how much of the study drug, LY2409021, gets into the blood stream and how long it takes the body to get rid of it when given to participants with different levels of kidney function. There were five study groups. Each participant only enrolled in one group. Participants in groups 1 through 4 were healthy or have mild, moderate, or severe kidney disease. They completed one study period lasting about 29 days. Study group 5 enrolled participants with kidney disease who were on dialysis. They have completed two study periods which together last about 59 days. Screening was required within 21 days prior to the start of the study for all participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY2928057 in Hemodialysis Participants

NCT01991483

Renal Insufficiency, Chronic Kidney Disease, Chronic

COMPLETED PHASE1

A Study of LY3502970 in Participants With Normal and Impaired Renal Function

NCT05936138

Renal Insufficiency Healthy

COMPLETED PHASE1

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function

NCT02191228

Renal Insufficiency

COMPLETED PHASE1

A Study of LY2623091 in Male and Females With Chronic Kidney Disease

NCT01427972

Chronic Kidney Disease

COMPLETED PHASE2

Study of LY3016859 in Participants With Diabetic Nephropathy

NCT01774981

Diabetic Nephropathy

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Failure, Chronic Renal Insufficiency, Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY2409021 Control

Healthy participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.

Group Type EXPERIMENTAL

LY2409021

Intervention Type DRUG

Administered orally

LY2409021 Mild Renal Impairment

Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.

Group Type EXPERIMENTAL

LY2409021

Intervention Type DRUG

Administered orally

LY2409021 Moderate Renal Impairment

Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.

Group Type EXPERIMENTAL

LY2409021

Intervention Type DRUG

Administered orally

LY2409021 Severe Renal Impairment

Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.

Group Type EXPERIMENTAL

LY2409021

Intervention Type DRUG

Administered orally

LY2409021 End Stage Renal Disease

Participants received a single 80 mg dose of LY2409021 orally on Day 1 of Period 1 of the study and a single 80 mg dose of LY2409021 orally on Day 1 of Period 2 of the study.

Group Type EXPERIMENTAL

LY2409021

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY2409021

Administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male participants must agree to use a reliable method of birth control in addition to having their partner use another method for the duration of the study and for 3 months after the last dose of LY2409021
* Female participants must not be of child-bearing potential
* Participants have a body mass index (BMI) of 18 to 40 kilogram per meter square (kg/m\^2), inclusive, at screening

\- Control participants must have normal renal function, assessed by mean estimated creatinine clearance (CLcr) greater than or equal to (≥)90 milliliter per minute (mL/min) at screening and day before dosing

\- Males or females with stable mild-to-severe renal impairment, assessed by estimated CLcr, or with ESRD requiring hemodialysis (or hemodiafiltration) for at least 3 months

\- Participants with T2DM that are being treated with diet or exercise alone or receive treatment with insulin

Exclusion Criteria

* Participants that require peritoneal dialysis
* Participants that have a current, functioning, organ transplant
* Participants who show evidence of significant active uncontrolled endocrine or autoimmune abnormalities (for example, thyroid disease, pernicious anemia) as judged by the screening physician
* Participants who had a febrile illness within 3 days prior to screening
* Participants with an abnormality in the 12-lead Electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study. \[Participants with a QT interval corrected using Fridericia's (QTcF) formula \>450 millisecond (msec) or a PR interval \>0.22 sec on the screening ECG, or who have risk factors for Torsades de Pointes\]
* Participants who show evidence of significant active neuropsychiatric disease
* Participants that are currently using or intend to use potent inhibitors of cytochrome P450 (CYP)3A, which include but are not limited to atazanavir, indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, and telithromycin
* Participants who are currently using drugs with a narrow therapeutic index (for example, digoxin,lithium, phenytoin, theophylline, and warfarin)
* Participants that are currently using drugs that are known to prolong the QT interval

* Participants that have used any drug indicated for medical care of the participant's renal impairment, which is not established in dose and administered for at least 7 days before LY2409021 administration
* Participants with poorly controlled hypertension (systolic blood pressure (BP) less than (\>)160, diastolic BP \>95 mm Hg) and/or evidence of labile blood pressure including symptomatic postural hypotension
* Participants with hemoglobin \<9 grams per deciliter (g/dL) or significant active hematologic disease from causes other than underlying renal disease

* Participants who use an oral or injectable antihyperglycemic agent, except for insulin, within 1 month prior to dosing (Day 1)
* Participants who have experienced a ketoacidotic episode (pH \<7.3) requiring hospitalization in the last 6 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes